Welcome to our dedicated page for Cyclacel Phar Pr SEC filings (Ticker: CYCCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CYCCP SEC filings page on Stock Titan aggregates regulatory documents for Cyclacel Pharmaceuticals, Inc., the issuer of the 6% Convertible Exchangeable Preferred Stock trading under symbol CYCCP on The Nasdaq Capital Market. These filings provide detailed information on the company’s oncology development activities, capital structure and corporate changes, and are a primary source for understanding the rights and risks associated with the preferred stock.
Investors can review Form 8-K current reports that describe material events such as private placements of Series F Convertible Preferred Stock and related series A, B and C common stock purchase warrants, warrant exchange agreements, amendments to preferred stock terms, and reverse stock splits of the common stock. Certain 8-K filings also discuss changes in the company’s independent registered public accounting firm and include the prior auditor’s statement that limited cash resources raised substantial doubt about the company’s ability to continue as a going concern.
Filings linked to CYCCP also cover shareholder approvals and strategic transactions. For example, an 8-K details the results of a special meeting where shareholders approved the issuance of Cyclacel common stock to FITTERS Diversified Berhad in connection with the acquisition of Fitters Sdn. Bhd., the potential issuance of more than 20% of the outstanding common stock under Nasdaq rules, and an amendment to change the corporate name to Bio Green Med Solution, Inc. Additional 8-K and 8-K/A filings note the adoption of an updated logo and reference the company’s new name and ticker symbol for its securities.
Registration statements such as the Form S-1 provide further context by registering shares of common stock underlying the Series F Preferred Stock and warrants, and by including business descriptions that characterize Cyclacel as a clinical-stage biopharmaceutical company focused on cancer medicines based on cell cycle, epigenetics, transcriptional regulation and mitosis biology. These documents often incorporate audited or reviewed financial statements and risk factor discussions.
On Stock Titan, AI-powered tools summarize key points from lengthy filings, highlight items relevant to CYCCP holders—such as dividend rights, conversion features, ownership limitations and subsequent amendments—and surface disclosures on liquidity, going concern language and major transactions. Real-time updates from EDGAR mean new 8-K, 10-Q, 10-K, S-1 and related filings appear promptly, enabling users to quickly see how Cyclacel’s preferred stock, common equity and corporate profile are described in its official SEC submissions.
Cyclacel Pharmaceuticals (CYCCP) filed a DEFA14A Amendment No. 1 to its 2025 proxy statement.
The sole revision corrects total shares outstanding on the May 1, 2025 record date from 381,202,294 to 356,357,531. No other sections, proposals or compensation disclosures were modified. All previously distributed proxy materials and voting matters remain unchanged for the virtual annual meeting scheduled on June 30, 2025.
Cyclacel Pharmaceuticals, Inc. (CYCC/CYCCP) filed an 8-K announcing a private placement of Series F Convertible Preferred Stock and accompanying warrants that closed on 20 June 2025. The company entered into a Securities Purchase Agreement with accredited investors for 3 million shares of Series F Preferred Stock at $1.00 per share, generating $3.0 million in gross proceeds to be used for general corporate and operating purposes.
Dilution mechanics: Each preferred share converts into 3.27 common shares, implying an effective conversion price of roughly $0.31 per common share. Full conversion would create up to ≈9.81 million new common shares, subject to a 4.99 % ownership cap per investor until stockholder approval is obtained. In addition, investors received 29.43 million five-year warrants split into three tranches with exercise prices of $0.51 (Series A), $0.60 (Series B) and $0.68 (Series C) per share. The warrants and preferred shares were issued under Regulation S and are therefore unregistered.
Governance & rights: The Series F Preferred votes with common stock on an as-converted basis (subject to the ownership cap), participates in common dividends, and carries a $1.00 per-share liquidation preference pari passu with other preferred stock. The company has committed to seek stockholder approval for the full issuance of common shares underlying the preferred and the warrants to comply with Nasdaq rules.
Key implications: The financing provides near-term liquidity but introduces the potential for significant future share dilution—up to ~39.2 million additional common shares if all instruments are exercised/converted. Investor approval risk, dilution magnitude, and relatively low effective conversion price are material considerations for existing shareholders.